Callahan, Margaret

Publications

Sort by

Co-Author Network

selected publications

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA oncology. 2020 Academic Article GET IT
Times cited: 92
Treatment Outcomes of Immune-Related Cutaneous Adverse Events. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 134
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 147
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI cancer spectrum. 2018 Review GET IT
Times cited: 70
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 574
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer cell. 2018 Academic Article GET IT
Times cited: 648
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 343
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer medicine. 2018 Academic Article GET IT
Times cited: 73
Introduction by the Guest Editors: The PD-1 Axis in Cancer Therapy: The Irony in a Name. Cancer journal (Sudbury, Mass.). 2018 Review GET IT
Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA oncology. 2018 Academic Article GET IT
Times cited: 109
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Academic Article GET IT
Times cited: 132
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2017 Academic Article GET IT
Times cited: 2369
Health-related quality of life results from the phase III CheckMate 067 study. European journal of cancer (Oxford, England : 1990). 2017 Academic Article GET IT
Times cited: 65
OncoKB: A Precision Oncology Knowledge Base. JCO precision oncology. 2017 Academic Article GET IT
Times cited: 394
Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2017 Academic Article GET IT
Times cited: 12
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 49
Corrigendum: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2016 Academic Article GET IT
Times cited: 29
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet. Oncology. 2016 Academic Article GET IT
Times cited: 525
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 703
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. The oncologist. 2016 Academic Article GET IT
Times cited: 128
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma research. 2016 Academic Article GET IT
Times cited: 27
Targeting T Cell Co-receptors for Cancer Therapy. Immunity. 2016 Review GET IT
Times cited: 358
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder cancer (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 135
Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. Head & neck. 2016 Academic Article GET IT
Times cited: 56
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nature communications. 2016 Academic Article GET IT
Times cited: 663
Reply to A. Indini et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Checkpoint Blockade for the Treatment of Advanced Melanoma. Cancer treatment and research. 2016 Review GET IT
Times cited: 37
Immune Checkpoint Therapy in Melanoma. Cancer journal (Sudbury, Mass.). 2016 Review GET IT
Times cited: 11
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 749
Safety of Infusing Ipilimumab Over 30 Minutes. 2015 GET IT
Times cited: 20
Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in oncology. 2015 Review GET IT
Times cited: 18
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 5387
On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science translational medicine. 2015 Review GET IT
Times cited: 123
Immune Checkpoint Blockade in Cancer Therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Review GET IT
Times cited: 1928
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. Journal of immunology (Baltimore, Md. : 1950). 2014 Academic Article GET IT
Times cited: 313
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science translational medicine. 2014 Academic Article GET IT
Times cited: 465
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-related cancer. 2014 Review GET IT
Times cited: 318
Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies. 2014 GET IT
Times cited: 67
Palliative and end-of-life care: precepts and ethics for the orthopaedic population. Orthopedic nursing. 2014 Review GET IT
Immune modulation in cancer with antibodies. Annual review of medicine. 2013 Review GET IT
Times cited: 397
Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Current oncology reports. 2013 Review GET IT
Times cited: 17
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013 Academic Article GET IT
Times cited: 150
Nivolumab plus ipilimumab in advanced melanoma. The New England journal of medicine. 2013 Academic Article GET IT
Times cited: 3352
Ipilimumab for patients with advanced mucosal melanoma. The oncologist. 2013 Academic Article GET IT
Times cited: 125
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of leukocyte biology. 2013 Review GET IT
Times cited: 271
Hepatotoxicity with combination of vemurafenib and ipilimumab. The New England journal of medicine. 2013 Letter GET IT
Times cited: 593
Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 121
Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clinics in dermatology. 2013 Review GET IT
Times cited: 53
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer cell. 2012 Academic Article GET IT
Times cited: 397
Progression of RAS-mutant leukemia during RAF inhibitor treatment. 2012 GET IT
Times cited: 197
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nature medicine. 2012 Academic Article GET IT
Times cited: 2722
Abscopal effect in a patient with melanoma. The New England journal of medicine. 2012 Letter GET IT
Immunologic correlates of the abscopal effect in a patient with melanoma. 2012 GET IT
Times cited: 1584
The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?. Clinical cancer research : an official journal of the American Association for Cancer Research. 2012 Comment GET IT
Times cited: 26
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology. 2011 Letter GET IT
Times cited: 9
Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer journal (Sudbury, Mass.). 2011 Review GET IT
Times cited: 24
Improving the therapeutic benefits of ipilimumab. Oncology (Williston Park, N.Y.). 2010 Comment GET IT
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Seminars in oncology. 2010 Review GET IT
Times cited: 196
Implanted hepatic arterial infusion pumps. Cancer journal (Sudbury, Mass.). 2010 Review GET IT
Times cited: 11
Treating human cancers with heat shock protein-peptide complexes: the road ahead. Expert opinion on biological therapy. 2009 Academic Article GET IT
Times cited: 30
Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proceedings of the National Academy of Sciences of the United States of America. 2008 Academic Article GET IT
Times cited: 81
Heat shock up-regulates lmp2 and lmp7 and enhances presentation of immunoproteasome-dependent epitopes. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 32
Resistance to CD4+CD25+ regulatory T cells and TGF-beta in Cbl-b-/- mice. Journal of immunology (Baltimore, Md. : 1950). 2004 Academic Article GET IT
Times cited: 113
Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. The Journal of biological chemistry. 2002 Academic Article GET IT
Times cited: 58
Hsp70, an immunological actor playing with the intracellular self under oxidative stress. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2002 Review GET IT
Times cited: 45

more ...

less ...

Background

education and training

M.D., Ph.D., University of Connecticut School of Medicine 2007
B.S., University of Connecticut 1998

Contact

full name

Margaret Callahan

VIVO Weill Cornell Medical College

Margaret Callahan Assistant Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name